Information Provided By: 
Fly News Breaks for July 13, 2015
BLUE
Jul 13, 2015 | 08:56 EDT
Roth Capital believes that bluebird bio remains well-positioned, partly due to what it sees as the company's "unambiguous data, defined path to market, and evolving immunotherapy program." The firm expects the stock to rebound in Q4 heading into the ASH meeting, and it recommends buying the stock on dips.
News For BLUE From the Last 2 Days
There are no results for your query BLUE
